Literature DB >> 17725605

Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours.

Jasper Manning1, Marie Indrova, Barbora Lubyova, Hana Pribylova, Jana Bieblova, Jiri Hejnar, Jana Simova, Tana Jandlova, Jan Bubenik, Milan Reinis.   

Abstract

Epigenetic events play an important role in tumour progression and also contribute to escape of the tumour from immune surveillance. In this study, we investigated the up-regulation of major histocompatibility complex (MHC) class I surface expression on tumour cells by epigenetic mechanisms using a murine tumour cell line expressing human E6 and E7 human papilloma virus 16 (HPV16) oncogenes and deficient in MHC class I expression, as a result of impaired antigen-presenting machinery (APM). Treatment of the cells with the histone deacetylase inhibitor Trichostatin A, either alone or in combination with the DNA demethylating agent 5-azacytidine, induced surface re-expression of MHC class I molecules. Consequently, the treated cells became susceptible to lysis by specific cytotoxic T lymphocytes. Further analysis revealed that epigenetic induction of MHC class I surface expression was associated with the up-regulation of APM genes [transporter associated with antigen processing 1 (TAP-1), TAP-2, low-molecular-mass protein 2 (LMP-2) and LMP-7]. The results demonstrate that expression of the genes involved in APM are modulated by epigenetic mechanisms and suggest that agents modifying DNA methylation and/or histone acetylation have the potential to change the effectiveness of antitumour immune responses and therapeutically may have an impact on immunological output.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17725605      PMCID: PMC2433299          DOI: 10.1111/j.1365-2567.2007.02689.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  41 in total

1.  Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma.

Authors:  U Ritz; F Momburg; H Pilch; C Huber; M J Maeurer; B Seliger
Journal:  Int J Oncol       Date:  2001-12       Impact factor: 5.650

2.  Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A.

Authors:  M Yoshida; M Kijima; M Akita; T Beppu
Journal:  J Biol Chem       Date:  1990-10-05       Impact factor: 5.157

3.  MethPrimer: designing primers for methylation PCRs.

Authors:  Long-Cheng Li; Rajvir Dahiya
Journal:  Bioinformatics       Date:  2002-11       Impact factor: 6.937

4.  Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma.

Authors:  Yan Nie; Jie Liao; Xin Zhao; Yunlong Song; Guang-yu Yang; Li-Dong Wang; Chung S Yang
Journal:  Carcinogenesis       Date:  2002-10       Impact factor: 4.944

Review 5.  DNA methylation, chromatin inheritance, and cancer.

Authors:  M R Rountree; K E Bachman; J G Herman; S B Baylin
Journal:  Oncogene       Date:  2001-05-28       Impact factor: 9.867

6.  Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors.

Authors:  W J Magner; A L Kazim; C Stewart; M A Romano; G Catalano; C Grande; N Keiser; F Santaniello; T B Tomasi
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

7.  Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.

Authors:  Romana Mikysková; Jan Bubeník; Vladimír Vonka; Michal Smahel; Marie Indrova; Jana Bieblová; Jana Símová; Tána Jandlová
Journal:  Int J Oncol       Date:  2005-02       Impact factor: 5.650

8.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

9.  Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16.

Authors:  M Smahel; E Sobotková; J Bubeník; J Símová; R Zák; V Ludviková; R Hájková; J Kovarík; F Jelínek; C Povýsil; J Marinov; V Vonka
Journal:  Br J Cancer       Date:  2001-02-02       Impact factor: 7.640

10.  Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression.

Authors:  P J Keating; F V Cromme; M Duggan-Keen; P J Snijders; J M Walboomers; R D Hunter; P A Dyer; P L Stern
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

View more
  32 in total

1.  Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas.

Authors:  Xiaoguang Wang; Brittany C Waschke; Rachel A Woolaver; Zhangguo Chen; Gan Zhang; Anthony D Piscopio; Xuedong Liu; Jing H Wang
Journal:  Cancer Immunol Res       Date:  2019-06-24       Impact factor: 11.151

2.  A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.

Authors:  Theodoros N Teknos; J Grecula; A Agrawal; M O Old; E Ozer; R Carrau; S Kang; J Rocco; D Blakaj; V Diavolitsis; B Kumar; P Kumar; Q Pan; M Palettas; L Wei; R Baiocchi; P Savvides
Journal:  Invest New Drugs       Date:  2018-12-19       Impact factor: 3.850

Review 3.  The human papillomavirus E7 oncoprotein as a regulator of transcription.

Authors:  William K Songock; Seong-Man Kim; Jason M Bodily
Journal:  Virus Res       Date:  2016-11-08       Impact factor: 3.303

4.  Effect of 5-aza-2'-deoxycytidine on immune-associated proteins in exosomes from hepatoma.

Authors:  Wen-Hua Xiao; Gao-Wa Sanren; Jian-Hua Zhu; Qiu-Wen Li; Huan-Rong Kang; Ru-Liang Wang; Lin-Ping Song; Ming Ye
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

Review 5.  Chromatin dependencies in cancer and inflammation.

Authors:  Ivan Marazzi; Benjamin D Greenbaum; Diana H P Low; Ernesto Guccione
Journal:  Nat Rev Mol Cell Biol       Date:  2017-11-29       Impact factor: 94.444

6.  Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.

Authors:  Ailsa J Christiansen; Alison West; Kellie-Marie Banks; Nicole M Haynes; Michele W Teng; Mark J Smyth; Ricky W Johnstone
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-22       Impact factor: 11.205

7.  Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis.

Authors:  Daniel J Lindner; Yan Wu; Rebecca Haney; Barbara S Jacobs; John P Fruehauf; Ralph Tuthill; Ernest C Borden
Journal:  Matrix Biol       Date:  2012-11-30       Impact factor: 11.583

8.  LMP gene promoter hypermethylation is a mechanism for its down regulation in Kazak's esophageal squamous cell carcinomas.

Authors:  Feng Zheng; Ayshamgul Hasim; Juret Anwer; Madiniyet Niyaz; Ilyar Sheyhidin
Journal:  Mol Biol Rep       Date:  2013-01-03       Impact factor: 2.316

9.  Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma.

Authors:  Irina V Tiper; Tonya J Webb
Journal:  Cancer Immunol Immunother       Date:  2016-09-10       Impact factor: 6.968

Review 10.  Targeting the epigenetic regulation of antitumour immunity.

Authors:  Simon J Hogg; Paul A Beavis; Mark A Dawson; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2020-09-14       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.